Researchers publish consensus statement on patient selection and appropriate use of Lu-177 PSMA-617 radionuclide therapy

The Society of Nuclear Medication and Molecular Imaging (SNMMI) has issued a brand new consensus assertion to offer standardized steerage for the choice and administration of metastatic castrate-resistant prostate most cancers (mCRPC) sufferers being handled with ¹⁷⁷Lu-PSMA radionuclide remedy.

The assertion, printed in The Journal of Nuclear Medicationadditionally opinions present scientific struggles physicians face throughout therapy with ¹⁷⁷Lu-PSMA-617 radionuclide remedy.

Just lately, the U.S. Meals and Drug Administration accredited ¹⁷⁷Lu-PSMA-617 for the therapy of males with mCRPC after progressing on taxane-based chemotherapy and a minimum of one line of androgen receptor pathway inhibitors (ARPI). To develop the affected person choice standards and decide applicable use situations, SNMMI assembled an autonomous work group to signify a multidisciplinary panel of well being care suppliers with substantive data in using nuclear medicine in ¹⁷⁷Lu-PSMA-617 radionuclide remedy. The work group performed a evaluation of the 4 potential part 2 and part 3 trials that used ¹⁷⁷Lu-PSMA-617 registered on clinicaltrials.gov to develop consensus suggestions.

When it comes to affected person choice, work group members agreed that PSMA PET needs to be carried out inside three months of therapy or since development on the final remedy to make sure that the present illness state is represented. If illness development or intervening remedy is clear, PSMA PET needs to be repeated. Both ¹⁸F-DCFPyL or ⁶⁸Ga-PSMA-11 can be utilized for PSMA PET imaging, and ¹⁸F-FDG PET is just not required as a regular affected person choice instrument. As well as, sufferers needs to be imaged with both contrast-enhanced CT or MRI to determine potential PSMA-negative illness. Baseline necessities for renal and bone marrow features have been additionally famous.

Therapy of mCRPC after chemotherapy and ARPI was thought-about applicable, whereas therapy of mCRPC after ARPI and earlier than chemotherapy was thought-about hardly ever applicable. The working group additionally agreed that therapy of sufferers with metastatic castration-sensitive prostate cancer was hardly ever applicable.

Moreover, the consensus assertion addressed present scientific struggles that physicians face when administering ¹⁷⁷Lu-PSMA-617 radionuclide remedy. These embody the position of androgen receptor-targeted therapies, the position of ²²³Ra, treatment-related toxicities, when to contemplate cessation of therapy, distinctive responders and restarting therapy, and imaging throughout therapy.

“With the approval of ¹⁷⁷Lu-PSMA-617, a brand new class of therapeutics is obtainable to sufferers with prostate most cancers. We look ahead to the potential use of PSMA radionuclide remedy in pre-chemotherapy mCRPC or different settings pending the complete outcomes of ongoing trials,” famous the authors.

Supplied by
Society of Nuclear Medication and Molecular Imaging